In summary, our study demonstrates that elevation of O-GlcNAcylation in a mouse model of PD through GlcN supplementation or OGT overexpression has the potential to alleviate PD, possibly by reprogramming mitochondrial function and reducing neuroinflammation in the SN. Here, OGT is linked to Parkinson disease.